High potency APIs, highly potent compounds, HAPI, HPAPI – there are many ways to communicate the hazard but the one thing that remains constant throughout are the high risks when manufacturing these active pharmaceutical ingredients. Experts are seeing a rise in the number of drug products being produced that contain highly potent compounds, but manufacturing processes are not developing accordingly when it comes to increased safety and reduced risk.
Unlike the tobacco industry, the pharmaceutical industry can’t put health warnings on the side of highly potent APIs in order to inform the population, as they do on the side of cigarette packets. Yet there are still lessons to be learnt when it comes to protecting personnel, as well as revenue and reputation, from the devastating effects a manufacturing safety breach could have.
The HPAPI World Congress explores how to mitigate the risks associated with manufacturing highly potent compounds so that regardless of whether you are part of the Executive Committee, or the technician handling toxic powder, you know that your HPAPI operations are safe and secure.
By joining us for a series of keynotes, presentations, workshops and roundtables, you will learn best practices and how to guides on subjects such as handling, containment, processing, exposure and monitoring. Explore the best ways to understand the potent hazard and communicate the risks, how then to translate this knowledge on the ground, options for outsourcing or in-house production, and finally the wider business considerations when involved with highly potent API manufacturing.
The HPAPI market is gaining momentum and is being cited as one of the most important sectors within the entire pharmaceutical industry, so there has never been a better time to get involved and gain a competitive advantage.
This content is blocked. Accept cookies to view the content.